Exclusion criteria | |
---|---|
Treatment | Currently participating in a clinical trial of a systemic anti-cancer treatment |
Physical health | Pregnant or lactating BMI < 18.5 |
Diagnosis of cerebral metastases | |
Karnofsky performance scores below 50 or other physical limitations that preclude participation in weekly psychotherapy and microdosing of LSD | |
Lab work | Liver function test > 3 times the upper limit of normal or creatinine clearance < 30 mL/min |
Diagnosis | Have a current diagnosis or history of any medical condition that could make receiving a sympathomimetic drug harmful because of potential increases in blood pressure and heart rate as assessed by a study physician |
Vital signs | Cardiovascular conditions including abnormal heart rate seen by ECG |
Blood pressure not exceeding 160 mmHg (systolic) and 90 mmHg (diastolic) (measured at three time points) | |
Mental health | |
Diagnosis | Lifetime history of schizophrenia or other psychotic disorders, or bipolar I or II disorder as assessed by the Standard MINI (Standard version 7.0.2) |
A current diagnosis of PTSD, panic disorder, agoraphobia, OCD, anorexia, and bulimia as assessed by the Standard MINI (Standard version 7.0.2) | |
Current risk | Elevated risk of suicide as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) or by a study psychiatrist |
Drug use | Any lifetime history of psychedelic microdosing; defined as repeated low-dose psychedelic usage for more than a week at a time |
Use of a psychedelic within the last year | |
Recent or current use of illicit drugs including methamphetamine, heroin, and synthetic cannabis. Other non-prescribed drugs will prompt exclusion at the discretion of a study physician | |
Current THC/cannabis usage will prompt exclusion if the participant does not agree to cease. However, CBD is permitted, and usage will be recorded |